newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results

$39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas, May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial